盐酸奥丹西隆与其它药物配伍的稳定性

王明仲(襄樊 441021 湖北襄樊市中心医院药学部)

盐酸奥丹西隆(Ondansetron hydrochloride,Ond)为英国葛兰素公司1989年开发成功的高度选择性5-HT_3受体拮抗剂,商品名为枢复宁(zofran),用于放疗、化疗时镇吐效果显著。我国宁波天衡制药厂自1996年正式生产,商品名枢丹。由于肿瘤患者用药的复杂性,许多学者竟相研究了Ond常用浓度(0.03~0.3 mg/ml)下与其它药物的配伍性,本文予以综合介绍(见表1),以利用药参考。

表1 盐酸奥丹西隆与其它药物配伍的稳定性

	配伍药物	浓度/mg·ml⁻¹	溶媒	Ond浓度/mg·ml⁻¹	容器	贮存条件	观察指标	稳定时间	参考文献
	10%葡萄糖(10%GS)			0.08	d	室温	Y	>24h	1
	5%葡萄糖(5%GS)			0.03,0.3		-20℃,5℃,25℃	Y	>24h	2,3
	生理盐水(NS)			0.03,0.08,0.3	d	-20℃,5℃,25℃	Y	>24h	1,2
	葡萄糖氯化钠注射液			0.08	d	室温	Y	>24h	1
	复方氯化钠注射液			0.08	d	室温	Y	>24h	1
	盐酸阿霉素	0.1,2	5%GS	0.03,0.3	a	室温,日光灯下	Y	>24h	4
	阿糖胞苷	0.2,40	5%GS	0.03,0.3	a	室温,日光灯下	Y	>24h	4
1△	达卡巴嗪	1,3	5%GS	0.03,0.3	a,c	4℃,30℃,日光灯下	Y	4~8h	4,5
	依托泊苷	0.1,0.4	5%GS	0.03,0.3	a	室温,日光灯下	Y	>24h	4
	甲氨蝶呤	0.5,6	5%GS	0.03,0.3	a	室温,日光灯下	Y	>24h	4
2△	硫酸长春新碱	0.014,0.028	NS	0.048,0.096	a,c	4℃,30℃	Y	>24h	5
	环磷酰胺	0.3,2	5%GS,NS	0.05,0.4		4℃,25℃	Y	>4d	6,7
	紫杉醇	1.2	5%GS	0.3,7.29	b	23℃	Y	>4h	8,9
	顺铂	0.200,0.455	NS	1.091,0.480	a	2~8℃,30℃	Y	>24h	10
	噻替哌	1	5%GS	1	b	23℃;高、低照度光	X	>4h	11
	哌拉西林-他唑巴坦	40-5,80-10	NS	0.03,0.1,0.3	b	23℃,室光	Y	>4h	12
	氨曲南	20,40	5%GS	0.015,0.15,1	b	25℃	X	>4h	13,14
	头孢塔齐定(碳酸钠盐)	20	5%GS	0.015,0.15	b	25℃	X	>4h	13
	头孢唑啉钠	10	5%GS	0.015,0.15	b	25℃	X	>4h	13
	氟康唑	1	NS	0.015,0.15	b	25℃	X	>4h	13
3△	米诺配能(meropenam)	1,20,50	NS	1	b,d	室温,日光灯下	X	0(沉淀)	15
	头孢美唑钠	100	NS	2	a,b,c	室温,日光灯下	X	>1h	16
	硫酸吗啡	1	NS	0.1,1.0		4℃,22℃	X	>31d	17

王明仲,31岁。1989年毕业于同济医科大学药学系药学专业,主管药师

续表

	配伍药物	浓度/ mg·ml⁻¹	溶媒	Ond 浓度 / mg·ml⁻¹	容器	贮存条件	观察指标	稳定时间	参考文献
	盐酸二氢吗啡	0.5	NS	0.1 ,1.0		4 ℃,22 ℃	X	>31 d	17
	remifentanil hydrochloride	0.025 ,0.25	NS	1	b	23 ℃	X	>4h	18
	苯碳酸顺阿曲库铵	0.1 ,2 ,5	5 %GS	1	b	23 ℃,高低照度光	X	>4h	19
	TPN(或 PN)		NS	0.03 ,0.3 ,1	b	室温,日光灯下	Y	>48h	20 ,21
4△	CsA	1.5	NS	0.32	b ,d	室温,日光灯下	X	?	22
	盐酸多巴胺	0.8	NS	0.32	b ,d	室温,日光灯下	X	>5h	22
	肝素钠	100u/ ml	NS ,5 %GS	0.32	b ,d	室温,日光灯下	X	>5h	22
5△	苹果汁、橘汁、果酒、樱桃饮料、碳酸类软饮料			0.067-2	d	-3 ~ 28 ℃	Y	>1h	23 ,24
	盐酸雷尼替丁	0.2 ,2.0	5 %GS	0.03 ,0.1 ,0.3	b	23 ℃	Y	>4h	8 ,25
6△	地塞米松	0.20 ,0.40	NS ,5 %GS	0.10 ,0.2 ,0.4 ,0.64	a	2 ~ 6 ℃,23 ℃	Y	>48h	26 ~ 28
	劳拉西泮	0.004	5 %GS	0.016 ,0.08	d	25 ℃	Y	>24h	26
	aldesleukin(重组白介素-2)	33800IU/ ml	5 %GS	0.7	b	室温,日光灯下	Z	>2h	29
	amifostine	10	5 %GS	1	b	23 ℃	X	>4h	30

注:a - 直接混合于 PVC 袋内;b - 模拟输液装置 Y 部等体积混合贮于 PVC 袋中;c - 在聚异戊二烯输液泵药池中;d - 玻璃容器;X - 外观;Y - 外观及含量;Z - 外观、含量及生物效价;1△ - Ond、盐酸阿霉素、达卡巴嗪三药配伍,30 ℃、日光灯下、PVC 袋内稳定 4 ~ 8h,聚异戊二烯输液泵药池中稳定 24h 以上;2△ - Ond、盐酸阿霉素、硫酸长春新碱三药配伍,30 ℃,日光灯下,a 或 c 容器内均稳定 24h 以上;3△ - Ond 1 mg/ ml 与米诺配能 1 mg/ ml NS 溶液配伍无沉淀;4△ - CsA 在 NS 中微粒超限,加入 Ond 后微粒无明显增加;5△ - Ond 加入热茶(75 ~ 85 ℃)中即刻变混浊;6△ - 高浓度的 Ond(0.64 mg/ ml)与地塞米松(0.40 mg/ ml)在聚丙烯注射器中沉淀(低浓度无),各浓度在工业聚脂 CR_3 袋内稳定 48h 以上

由附表可知,Ond 在常用浓度下可与许多药物配伍使用,这对减少患者被穿刺次数、医务人员工作量、患者不必要液体摄入均具有积极的临床意义。但应用中应注意配伍允许的浓度和稳定时限。Ond 一般不能与米诺配能配伍,与地塞米松配伍不能使用聚丙烯注射器具,Ond 可口服用药但不能加入热茶中饮用,是否能与环孢素 A(CsA)配伍尚不明确。

参考文献

1 徐济萍,张桂芳,张鉴.奥丹西隆注射液在 4 种输液中的稳定性.中国临床药学杂志,1997,6(1):31.

2 Bosso JA, Prince RA, Fox JL. Stability of ondansetron hydrochloride in injectable solutions at -20 ,5 ,25 ℃. Am J Hosp Pharm,1992,49:2225.

3 Thee SS, Jeona EWS, Chin A, *et al*. Stability of ondanstron hydrochloride stored in a disposable elastomeric in fusion device at 4 ℃. Am J Hosp Pharm,1993,50:1920.

4 王明仲摘.盐酸奥丹西隆与五种抗肿瘤药的配伍稳定性.国外医药-合成药、生化药、制剂分册,1997,18(3):189.

5 Stewart JT, Warren FW, King DT, *et al*. Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags. Am J Health-Syst Pharm,1997,54:915.

6 Fleming RA, Olsen DJ, Savage PD, *et al*. Stability of ondansetron hydrochloride and cyclophosphamide. Am J Health-Syst Pharm,1995,52(5):516.

7 徐济萍,张鉴,张桂芳.昂丹司琼注射剂与环磷酰胺注射剂的配伍稳定性.中国医院药学杂志,1997,17(6):263.

8 Burm JP, Jhee SS, Chin A, *et al*. Stability of paclitaxel with ondansetron hydrochloride or ranitidine hydrochloride during simulated Y-site administration. Am J Hosp Pharm,1994,51:1201.

9 Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm,1993,50:300.

10 Henry DW, Marshall JL, Nazzaro D, *et al*. Stability of cisplatin and ondansetron hydrochloride in admixtures for continuous infusion. Am J Health-Syst Pharm,1995,52:2570.

11 Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm,1996,53:1041.

12 Chung KC, Moon YSK, Chin A, *et al*. Compatibility of ondansetron hydrochloride and piperacillin sodium-tazobactam sodium during simulated Y-site administration. Am J Health-Syst Pharm,1995,52:1554.

13 Bosso JA, Prince RA, Fox JL, *et al*. Compatibility of ondansetron hydrochloride with fluconazole, ceftazidime, aztreonam, and cefazolin sodium under simulated Y-site conditions. Am J Hosp Pharm, 1994, 51: 389.

14 Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm, 1995, 52: 1086.

15 Patel PR. Compatibility of meropenam with commonly used injectable drugs. Am J Health-Syst Pharm, 1996, 53: 2853.

16 Hutchings SR, Rusho Wj, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-Site delivery. Am J Health-Syst Pharm, 1996, 53: 2185.

17 Trissel LA, Xu QY, Martinez JF, *et al*. Compatibility and stability of ondansetron hydrochloride with morphine sulfate and with hydromorphine hydrochloride in 0.9% sodium chloride injection at 4, 22, and 32 ℃. Am J Hosp Pharm, 1994, 51: 2142.

18 Trissel LA, Gilbert DL, Martinez JF, *et al*. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm, 1997, 54: 2192.

19 Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm, 1997, 54: 1735.

20 Kirkham JC, Rutherford ET, Cunningham GN, *et al*. Stability of ondansetron hydrochloride in a total parenteral nutrient admixture. Am J Health-Syst Pharm, 1995, 52: 1557

21 Trissel LA, Gilbert DL, Martinez JF, *et al*. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm, 1997, 54: 1295.

22 Najari Z, Rusho Wj. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm, 1997, 54: 181.

23 Graham CL, Dukes GE, Fox JL, *et al*. Stability of ondansetron hydrochloride injection in extemporaneously prepared oral solutions. Am J Hosp Pharm, 1993, 50: 106.

24 Yamreudeewong W, Danthi SN, Hill RA, *et al*. Stability of ondansetron hydrochloride injection in various beverages. Am J Health-Syst Pharm, 1995, 52: 2011.

25 Pompilio FM, Fox JL, Inagaki K, *et al*. Stability of ranitidine hydrochloride with ondansetron hydrochloride or fluconazole during simulated Y-site administration. Am J Hosp Pharm, 1994, 51: 394.

26 Mcguire TR, Narducci WA, Fox JL. Compatibility and stability of ondansetron hydrochloride, dexamethasone, and lorazepam in injectable solutions. Am J Hosp Pharm, 1993, 50(7): 1410.

27 Evrard B, Ceccato A, Gaspard O, *et al*. Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in 0.9% sodium chloride injection and in 5% dextrose injection. Am J Health-Syst Pharm, 1997, 54: 1065.

28 Hagan RL, Mallett MS, Fox JL. Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in infusion bags and syringes for 32 days. Am J Health-Syst Pharm, 1996, 53: 1431

29 Alex S, Gupta SL, Minor JR, *et al*. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm, 1995, 52: 2423.

30 Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm, 1995, 52: 2208.

收稿日期:1998-04-06